GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fredun Pharmaceuticals Ltd (BOM:539730) » Definitions » EV-to-EBIT

Fredun Pharmaceuticals (BOM:539730) EV-to-EBIT : 14.24 (As of May. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Fredun Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Fredun Pharmaceuticals's Enterprise Value is ₹4,998 Mil. Fredun Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹351 Mil. Therefore, Fredun Pharmaceuticals's EV-to-EBIT for today is 14.24.

The historical rank and industry rank for Fredun Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

BOM:539730' s EV-to-EBIT Range Over the Past 10 Years
Min: 1.15   Med: 16.25   Max: 46.54
Current: 14.24

During the past 13 years, the highest EV-to-EBIT of Fredun Pharmaceuticals was 46.54. The lowest was 1.15. And the median was 16.25.

BOM:539730's EV-to-EBIT is ranked better than
59.37% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs BOM:539730: 14.24

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Fredun Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹4,405 Mil. Fredun Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was ₹351 Mil. Fredun Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 7.97%.


Fredun Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for Fredun Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fredun Pharmaceuticals EV-to-EBIT Chart

Fredun Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.54 30.69 35.74 16.25 12.55

Fredun Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.25 12.56 15.12 11.40 12.55

Competitive Comparison of Fredun Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Fredun Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fredun Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fredun Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fredun Pharmaceuticals's EV-to-EBIT falls into.



Fredun Pharmaceuticals EV-to-EBIT Calculation

Fredun Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=4998.438/351.02
=14.24

Fredun Pharmaceuticals's current Enterprise Value is ₹4,998 Mil.
Fredun Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹351 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fredun Pharmaceuticals  (BOM:539730) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Fredun Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=351.02/4404.602468
=7.97 %

Fredun Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹4,405 Mil.
Fredun Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹351 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fredun Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Fredun Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Fredun Pharmaceuticals (BOM:539730) Business Description

Traded in Other Exchanges
N/A
Address
Ganpatrao Kadam Marg, 11th Floor, Urmi Estate, Lower Parel (West), Mumbai, MH, IND, 400013
Fredun Pharmaceuticals Ltd is an India based company engaged in the business of pharmaceuticals and healthcare. The company manufactures pharmaceutical formulations, nutraceuticals, herbal supplements, and dietary supplements. In addition, it also manufactures animal healthcare products through its group companies. It sells its products in India and also exports its formulations as branded generics to international countries.

Fredun Pharmaceuticals (BOM:539730) Headlines

No Headlines